Holen Sie sich die Stockscreener-App
2.81
4.42%
-0.13
Handel nachbörslich:
2.81
Aptevo Therapeutics Inc Aktie (APVO) Neueste Nachrichten
Weekly Recap: APVO H1 losses and Aug 13 financing via warrants, PIPE - TradingView
Aptevo Therapeutics (APVO): CVI and Heights disclose 6.3% warrant-based stake - Stock Titan
Aptevo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Aptevo Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Aptevo Therapeutics Inc. 6M 2026: Net loss $(13.15M), Diluted EPS $(11.19) — 10-Q Summary - TradingView
Aptevo APVO Reports Q2 2026 Update With $9.8 Million Cash - Quiver Quantitative
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results - ACCESS Newswire
Aptevo's Mipletamig Shows 81% Remission in 31 Leukemia Patients - Stock Titan
Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing - TipRanks
Aptevo raises $4.5 million through warrant and equity financing By Investing.com - Investing.com Nigeria
Aptevo Raises $4.5 Million Via Warrant Exercises and PIPE; Issues 5.6M Warrants at $4.03 - TradingView
Aptevo raises $4.5 million through warrant and equity financing - Investing.com
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds - ACCESS Newswire
New Aptevo warrants for 4.3M shares await stockholder approval - Stock Titan
Aptevo Therapeutics Inc. (APVO) Stock: New Financing Targets $4.5M in Gross Proceeds - Blockonomi
Aptevo raises $4.5M through warrant exercises and private placement By Investing.com - Investing.com Nigeria
Aptevo raises $4.5M through warrant exercises and private placement - Investing.com
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds - ACCESS Newswire
Aptevo’s Common Warrants Cover Up to 4.3M Shares, Need Approval - Stock Titan
Aptevo Therapeutics (APVO) Rises 1.49% to $4.08, Approaches Resistance at $4.28Wave Equality - dars.gov.et
Aptevo Therapeutics (APVO) CMO converts RSUs; 156 shares withheld for taxes - Stock Titan
Aptevo Therapeutics (APVO) director converts 400 RSUs into 400 common shares - Stock Titan
Aptevo Therapeutics (APVO) director converts 400 RSUs into common shares - Stock Titan
Aptevo Therapeutics (APVO) SVP SoYoung Kwon converts 638 RSUs to stock - Stock Titan
Aptevo Therapeutics (APVO) CFO exercises 638 RSUs into common stock - Stock Titan
Aptevo Therapeutics (APVO) director exercises RSUs, acquires 400 common shares - Stock Titan
Aptevo Therapeutics (APVO) director nets 400 common shares from RSU vesting - Stock Titan
Aptevo Therapeutics (APVO) Executive Chair exercises RSUs, withholds 406 shares for tax - Stock Titan
Aptevo Therapeutics Inc (APVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aptevo Therapeutics Inc expected to post a loss of $6.01 a shareEarnings Preview - TradingView
APVO Q2'26 Earnings: EPS estimate is (6.01) USD - tradingview.com
Aptevo Therapeutics Inc (APVO) Institutional Confidence - TradingKey
APVO Q2'26 Earnings: revenue estimate is 0 USD - TradingView
APVO|Aptevo Therapeutics Inc|Price:4.180|Chg%:+0.110 - tradingkey.com
Aptevo Therapeutics Inc (APVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aptevo Therapeutics Unveils New Solid Tumor Strategy - TipRanks
Aptevo Dips on Credit Line - Baystreet.ca
Aptevo Therapeutics Inc (APVO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aptevo files patent for Nectin-4 x PD-L1 cancer platform - Investing.com
Aptevo Filing May Support Radiopharmaceuticals and T-Cell Engagers - Stock Titan
Aptevo Therapeutics Inc (APVO) Cash Flow - TradingKey
Aptevo Therapeutics Inc (APVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aptevo Therapeutics Inc (APVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aptevo Therapeutics files patent for Nectin-4 x PD-L1 dual-targeting backbone - scanx.trade
APVO|Aptevo Therapeutics Inc|Price:4.209|Chg%:-0.181 - TradingKey
Aptevo Therapeutics Inc (APVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TradingKey - TradingKey
Aptevo Therapeutics Inc. Revenue Breakdown – NASDAQ:APVO - TradingView
Aptevo Therapeutics Inc (APVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
APVO|Aptevo Therapeutics Inc|Price:4.390|Chg%:+0.020 - TradingKey
Mary Jo Janatpour Net Worth (2026) - GuruFocus
Niowave, Inc. Net Worth (2026) - GuruFocus
Aptevo Therapeutics (APVO) Edges Higher: Testing Key Resistance Amid Steady VolumeNHNL Ratio - dars.gov.et
Aptevo Therapeutics Secures Grant for APVO451 Development - The Globe and Mail
Grant supports Aptevo’s immunotherapy APVO-451 for solid tumors - BioWorld News
Aptevo (NASDAQ: APVO) gets $1.5M CARE Fund grant to advance APVO451 - Stock Titan
Aptevo receives $1.5M grant for cancer therapy development - Investing.com
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors - The Joplin Globe
Price to sales forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Price to sales forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView
Aptevo Therapeutics (APVO) Edges Lower, Testing Key Support LevelsFlat Correction - dars.gov.et
Price to book forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
APVO Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Enterprise value to EBIT forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView
Price to earnings forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView
Aptevo Therapeutics, Inc. Actuals & Estimates (NASDAQ:APVO) - TradingView
Aptevo Therapeutics, Inc. Actuals & Estimates (MUN:AP82) - TradingView
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):